Apellis Pharmaceuticals: Validation of 4 Marketing Applications for Pegcetacoplan for Geographic Atrophy

Apellis Pharmaceuticals Validation for Pegcetacoplan
Apellis Pharmaceuticals (APLS) announced the receival of validation of its marketing applications by regulatory authorities in Canada, Australia, the United Kingdom, and Switzerland for intravitreal pegcetacoplan regarding the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The decisions by the local regulatory authorities in these four countries are . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.